Список проголосовавших за комментарий " <strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>IsoRay (<strong>ISR </strong>+0.52%) announces highlights from its presentation at the 21st Annual Meeting of the Society for Neuro-Oncology</li><li>Global Blood Therapeutics (<strong>GBT </strong>+3.22%) announces that the European Commission has designated GBT440 as an orphan medicinal product for the treatment of sickle cell disease</li><li>Sangamo Biosci (<strong>SGMO </strong>+3.85%) announces that its collaborative zinc finger nuclease-mediated genome editing program for hemoglobinopathies will transfer to Bioverativ</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Arrowhead (<strong>ARWR </strong>-62.76%) will discontinue development of clinical stage drug candidates ARC-520, ARC-521, and ARC-AAT</li><li>Cerecor (<strong>CERC </strong>-52.54%) announces top-line clinical results from its major depressive disorder Phase 2 clinical trial of adjunctive treatment of CERC-301; study misses primary endpoint</li><li>Ocular Therapeutix (<strong>OCUL </strong>-3.97%) enters into controlled equity offering sales agreement to offer and sell shares of its common stock having an aggregate offering price of up to $40 mln</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>Champions Oncology (<strong>CSBR </strong>+17.8%) reports Q3 EPS $0.00 vs ($0.20) year ago on revs +51.5% y/y to $4.5 mln and reaffirms annual revenue guidance; details new strategic emphasis</li><li>RA Pharma (<strong>RARX </strong>+0.52%) reports Q3 results; on track to initiate Phase 2 Clinical Trial of RA101495 in 1Q 2017</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Xtant Medical (<strong>XTNT </strong>+15.5%) initiated with a Buy at Aegis Capital; tgt $3.50</li><li>Arbutus Biopharma (<strong>ABUS </strong>+12.26%) Chardan Capital Markets Upgraded to BUY (from Neutral) — Price Target: 4</li><li>UnitedHealth (<strong>UNH </strong>+1.22%) target raised to $175 at RBC Capital Mkts</li><li>Abaxis (<strong>ABAX </strong>-2.53%) downgraded to Neutral from Buy at Northcoast</li></ul>"